6 Danish healthcare stocks with +20% return, index continues up and outperforms, Gubra’s CEO selling

Del indlægget:
Del indlægget.

NORDIC | BIOTECH & HEALTHCARE Your insights into listed Danish & Nordic biotech & healthcare stocks.

Last week the Nordic healthcare stocks delivered a strong performance. The KPHC index rose 2.4% and the Danish stocks rose 7.4%. Gubra’s CEO sold shares for around DKK 30 million, Acarix carried out a directed issue of SEK 21 million, and SynAct initiated the filing process for the phase IIb study with Resomelagon. Finally, CS Medica’s stock is now traded on XETRA, in a move for increased liquidity. 6 Danish healthcare stocks delivered a +20% return.

12 of the 22 Danish healthcare companies had a positive share price development the past week and 11 companies have had a positive share price performance year-to-date. Gubra is the best-performing Danish healthcare stock year-to-date with a 444% return and 2CureX was the best Nordic healthcare investment last week. 4 Danish healthcare stocks with +100% YTD return.

Stay tuned to the developments of impact companies and stocks in the Nordics with the NORDIC | IMPACT newsletter that helps you invest more sustainably in the businesses of tomorrow.

Register for the NORDIC | IMPACT newsletter

DANISH COMPANY NEWS

Acarix

Acarix carries out a directed issue of SEK 21 million (Link)

Ascendis Pharma

No news the past week

Biosergen

No news the past week

Cessatech

No news the past week

CS Medica

CS MEDICA Stock Now Also Traded on XETRA (Link)

Curasight

Directed issues registered at the Danish Business Authority (Link)

DanCann Pharma

DanCann Pharma A/S announces last day for trading in temporary shares (Link)

Evaxion Biotech

Evaxion Reinforces Milestone Timeline and Provides Shareholder Update (Link)

ExpreS2ion

ExpreS2ion resolves on a directed issue of units to guarantors in connection with the completed rights issue (Link)

ExpreS2ion announces U.S. patent issue notification for glyco-engineered immunization antigens (Link)

 ExpreS2ion announces final outcome of its rights issue (Link)

Fluoguide

No news the past week

Genmab

No news the past week

Gubra

The CEO sold shares worth around DKK 30 million.

Boehringer Ingelheim and Gubra announce start of clinical development of a potential first-in-class, triple agonist, obesity treatment (Link)

Initiator Pharma

No news the past week

IO Biotech

No news the past week

Pila Pharma

No news the past week

Saniona

No news the past week

Scandion Oncology

Scandion Oncology board member Michel Ducreux steps down, joins advisory board (Link)

SynAct Pharma

SynAct initiates filing process for Phase 2b ADVANCE study with resomelagon (Link)

ViroGates

No news the past week

Zealand Pharma

No news the past week

Y-mAbs Therapeutics

Y-mAbs Appoints Seasoned Biopharma Executive Peter Pfreundschuh as Chief Financial Officer (Link)

2cureX

No news the past week

SELECTED CASES

Curasight

Investment Case

SHARE PRICE DEVELOPMENTS – Danish stocks

On average, the Danish biotech and healthcare stocks delivered a very strong share price performance the past week of 7.5% compared to 2.4% for the KPHC index. 6 stocks rose more than 20% each. 2cureX became the best-performing stock without any notable news. Gubra rose 39% although the CEO sold shares worth around DKK 30 million, and SynAct Pharma 24% after they initiated the filing process for the phase IIb study with Resomelagon. Furthermore, Acarix had another week of great performance following a directed issue of SEK 21 million. Finally, CS Medicas stock is now traded on XETRA, in a move to increase liquidity.

The best stock year-to-date is Gubra followed by Pila Pharma with 444% and 206% increases after the first 6 months of trading. Zealand Pharma and Acarix have also made a +100% return year-to-date. Overall the Danish biotech and healthcare stocks are in positive territory this year with a year-to-date return of 32.7%.

Overview of share price developments the past week, year-to-date, and last twelve months

NORDIC BIOTECH & HEALTHCARE DEVELOPMENTS

In the past week, the all-Nordic index Kapital Partner Nordic Healthcare Index (KPHC) rose 2.4% to 69,20. The index has had a strong performance since the end of April, but last week the index took a hit. In the past 12 months, the KPHC index has significantly underperformed relative to large caps, while the venture/small cap Kapital Partner Nordic Growth Exchanges index (KPNGX) has followed the KPHC index’s downward trajectory down around 7%.

The index development for Kapital Partner Healthcare Index the past 12 months

The KPHC index includes all Nordic healthcare stocks. This means both Novo Nordisk and Genmab as well as Curasight.

39-62% in weekly return for the three best-performing Nordic biotech & healthcare stocks the past week

2CureX AB (62%) provides various tools that doctors use during treatment to measure the effect and resistance of cancer drugs on the patient’s own cancer cells. The goal is to shorten the treatment period and find the right personalised treatment. Today, the largest business is in the European market.

Aino Health AB (62%) is a SaaS company that offers a cloud platform for data-driven corporate health. The platform contains services on a subscription basis to increase well-being and productivity and reduce sickness absence in large, complex organizations and companies. The customers mainly consist of international companies and the public sector.

Gubra A/S (39%) is a research company focused on the development of drug candidates for the treatment of cancer, and especially aggressive lymphoma. Respiratorius also did a capital raise with 50% of shares being subscribed.

Sources: Refinitiv Eikon, Cision, Nordnet & company websites

Disclaimer 

Udvalgte investeringscases

CS Medica
Se her
Ekobot
Se her
Biosergen
Se her
Nexcom
Se her
Curasight
Se her
Mdundo
Se her
Previous slide
Next slide

Ønsker du at modtage et af vores nyhedsbreve? Udfyld venligst formularen nedenunder.

  • Investeringscases – Nyhedsbreve med top aktuelle investeringscases fra de nordiske vækstbørser og life science sektoren, og ugentlige markedsopdateringer..
  • Børsnoteringer – Opdateringer på nye og igangværende børsnoteringer i Skandinavien samt resultaterne af dem. (Nyhedsbrev fra Nyemission.dk)   
  • Nyheder – Nyheder fra og om Kapital Partner, herunder indsigt om kapitalmarkederne og børsnoteringer samt invitation til investormøder og- arrangementer.
  • Danish Biotech Weekly – Ugentlig opdatering med nyheder og kursudvikling for alle danske, børsnoterede selskaber uanset hvilket land eller børs de er noteret

*Hvis du ønsker information om vores kommende investeringsforening med fokus på de nordiske vækstbørser, herunder mulighed for at investere, så tilmeld dig nyhedsbrevet Nyheder.




Investornetværk:

Ønsker du at være en del af Kapital Partners investornetværk, hvor du får adgang til investeringer i selskaber og emissioner, samt indbydelse til investorrettede arrangementer
udfyld venligst formularen her.

Udvalgte cases

Curasight
Se her
Mdundo
Se her
Fluoguide
Se her

Mest læste indlæg

Selskabscases

Markedscases

Sectorcases

Tilbage til investeringscases

Kapital Partner A/S

Ewaldsgade 9

2200 København N
CVR: 37364843

Privatlivspolitik  –  Cookies

Skriv til os

Del indlægget på sociale media eller på email. 

LinkedIn
Facebook
Twitter
Email